Sociedad Americana de Hirudoterapia

Dirección Nacional de Farmacia y Drogas — Ministerio de Salud de Panamá

Panama DNFD · Panama · latin america

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Panama's National Directorate of Pharmacy and Drugs (Ministry of Health) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
latin america
Country
Panama
Leech status
unregulated
Last ASH review
2026-05-27

Relevant Regulation Codes

  • Panamanian Ley 1 de 2001 sobre medicamentos y otros productos para la salud humana
  • Panamanian national medical device regulatory framework
  • Central American Common Market (CACM/MCCA) harmonised pharmaceutical frameworks where applicable

Prescriber Requirements

  • Panamanian Colegio Médico–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

DNFD registration as applicable; Spanish-language labelling required by national law. Standard cold-chain conditions.

Import/Export Rules

DNFD and Ministerio de Desarrollo Agropecuario clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Caja de Seguro Social (CSS) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Central American regulatory frameworks rely on a mixture of national and regional harmonisation; whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.